Trial Profile
A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of MHAA4549A in Healthy Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 19 Jul 2016
Price :
$35
*
At a glance
- Drugs Gedivumab (Primary)
- Indications Influenza virus infections
- Focus Adverse reactions
- Sponsors Genentech
- 05 Jul 2016 Results published in the Antimicrobial Agents and Chemotherapy
- 21 Sep 2015 Results presented at the Joint 55th Interscience Conference on Antimicrobial Agents and Chemotherapy and 28th International Congress of Chemotherapy
- 21 Sep 2015 Non-compartmental PK analysis results from this trial and an another trial presented at the Joint 55th Interscience Conference on Antimicrobial Agents and Chemotherapy and 28th International Congress of Chemotherapy.